Title
Association of Retinal Vascular Caliber and Age-Related Macular Degeneration in Patients With the Acquired Immunodeficiency Syndrome.

Permalink
https://escholarship.org/uc/item/9th7d69p

Journal
Investigative ophthalmology & visual science, 59(2)

ISSN
0146-0404

Authors
Jabs, Douglas A
Van Natta, Mark L
Pak, Jeong Won
et al.

Publication Date
2018-02-01

DOI
10.1167/iovs.17-23334

Peer reviewed
Association of Retinal Vascular Caliber and Age-Related Macular Degeneration in Patients With the Acquired Immunodeficiency Syndrome

Douglas A. Jabs,1–3 Mark L. Van Natta,3 Jeong Won Pak,4 Ronald P. Danis,4 and Peter W. Hunt5
1Department of Ophthalmology, The Icahn School of Medicine at Mount Sinai, New York, New York, United States
2Department of Ophthalmology, The Icahn School of Medicine at Mount Sinai, New York, New York, United States
3Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States
4Department of Ophthalmology, The University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
5The Department of Medicine, The University of California, San Francisco School of Medicine, San Francisco, California, United States

Purpose. To evaluate the relationship between retinal vascular caliber and AMD in patients with AIDS.

Methods. Participants enrolled in the Longitudinal Study of the Ocular Complications of AIDS had retinal photographs taken at enrollment. Retinal vascular caliber (central retinal artery equivalent [CRAE] and central retinal vein equivalent [CRVE]) and intermediate-stage AMD were determined from these retinal photographs. Photographs were evaluated by graders at a centralized reading center, using the Age-Related Eye Disease Study grading system for AMD and semiautomated techniques for evaluating retinal vascular caliber.

Results. Of the 1171 participants evaluated, 110 (9.4%) had AMD and 1061 (90.6%) did not. Compared with participants without AMD, participants with AMD had larger mean CRAEs (151 ± 16 μm versus 147 ± 16 μm; P = 0.009) and mean CRVEs (228 ± 24 μm versus 223 ± 25 μm; P = 0.02). The unadjusted differences were: CRAE, 4.3 μm (95% confidence interval [CI] 1.1–7.5; P = 0.009) and CRVE, 5.5 μm (95% CI 0.7–10.3; P = 0.02). After adjustment for age, race/ethnicity, sex, human immunodeficiency syndrome (HIV) transmission category, smoking, enrollment and nadir CD4+ T cells, and enrollment and maximum HIV load, the differences between patients with and without AMD were as follows: CRAE, 5.4 μm (95% CI 2.3–8.5; P = 0.001) and CRVE, 6.0 μm (95% CI 1.4–10.6; P = 0.01).

Conclusions. In patients with AIDS, AMD is associated with greater retinal arteriolar and venular calibers, suggesting a role for shared pathogenic mechanisms, such as persistent systemic inflammation.

Keywords: acquired immunodeficiency syndrome, age-related macular degeneration, retinal vascular caliber

AMD is a leading cause of visual impairment and blindness in persons older than 65 years.1,2 Although there are regional differences in the prevalence of AMD, globally, it is estimated that the number of persons with AMD will be 196 million in 2020 and 288 million by 2040.3 AMD typically is staged as early, intermediate, or late. Early-stage AMD consists of small drusen. Intermediate-stage AMD consists of extensive medium-size drusen or any large drusen, with or without pigment changes. Late-stage AMD is defined by the presence of either choroidal neovascularization or geographic atrophy.4–7 Antiretroviral-treated, immune-restored, human immunodeficiency virus (HIV)-infected persons have a marked reduction in the incidence of opportunistic infections and a substantially increased life span compared with those from the era before modern combination antiretroviral therapy (cART).8–11 Despite these improvements, antiretroviral-treated, immune-restored, HIV-infected persons have a substantially shortened life span compared with similarly aged, HIV-uninfected peers, which largely is due to an increased risk of non-AIDS diseases associated with aging (e.g., cardiovascular disease, non-AIDS cancers, metabolic diseases, and neurocognitive decline).12–16 This increased risk of age-related diseases suggests that antiretroviral-treated, immune-restored, HIV infection is associated with an “accelerated and/or accentuated aging” phenotype.17,18 Consistent with this accentuated aging, patients with AIDS have an approximately 4-fold increased age- and sex-adjusted prevalence of intermediate-stage AMD and an approximately 1.75-fold increased race- and sex-adjusted incidence of intermediate-stage AMD when compared with that in HIV-uninfected cohorts.17,18 Patients with AIDS also have retinal vascular calibers consistent with those of HIV-uninfected persons who are on average 10 years older, again consistent with an accelerated/accidented aging phenotype.19 Therefore, we investigated the relationship between AMD and retinal
vascular caliber in persons with AIDS enrolled in the Longitudinal Study of the Ocular Complications of AIDS (LSOCA).

**Methods**

LSOCA was a prospective, observational, cohort study of patients with AIDS in the era of modern cART.20,21 Enrollment began on September 1, 1998, and was completed on July 31, 2011. All participants had AIDS diagnosed according to the 1993 Centers for Disease Control and Prevention revised criteria for the diagnosis of AIDS.22 Recruitment occurred at 19 clinical centers throughout the United States, typically located in urban centers with a large HIV-infected population.20 Participants with and without ocular opportunistic infections were recruited.

At enrollment, all participants gave a detailed medical and HIV-related disease history; relevant findings were confirmed from the medical record. Fifty to 60-degree retinal photograph of the disc and macula were taken at enrollment, as previously described.17,18 Laboratory testing at enrollment included hematology and blood chemistry, blood CD4+ T cells, the amount of circulating HIV RNA in the blood (HIV load), and the presence of antibodies to hepatitis C.20,21 Approval for the study and its procedures was obtained from the institutional review boards of the individual participating clinical centers and the three resource centers (chairman’s office, coordinating center, and reading center). Written, informed consent was obtained from all participants. The study was conducted in accordance with the principles of the Declaration of Helsinki.

**Grading of Retinal Photographs**

Photographs were graded at the Studies of the Ocular Complications of AIDS (SOCA) Reading Center at the University of Wisconsin from stereoscopic color photographs of the macula obtained at enrollment. Photographers and camera systems were certified for SOCA photographic procedures by reading center personnel. Images were graded either from 35-mm film, mounted in typical slide mounts and viewed on a light box with a Donaldson 5X stereoscopic viewer, or from digital images displayed on calibrated computer monitors and viewed with a stereoscopic viewer (PS Manufacturing, Portland, OR, USA). The Early Treatment Diabetic Retinopathy Grid, measuring 7.2 mm on the retina, was placed on film slides using an acetate overlay sized for the camera type and degree of view.5,17,18 Digital image grading used software tools to calibrate and locate the grid.7,17,18 Approximately 10% of the enrollment photographs were digital. Grading of digital images at a reading center for AMD has been demonstrated to be comparable with that of film images.22 Fundus photographs were graded for the features of intermediate-stage AMD, including the presence, size, and area of drusen, and the presence and area of pigmentary abnormalities. Grading procedures were based on the Age-Related Eye Disease Study system for classifying AMD from retinal photographs.22 Graders were masked as to clinical information. The outcome of interest was the presence of intermediate-stage AMD, defined as at least one large druse (>150 μm using modern estimates of the average disc size or >125 μm using the traditional estimate) or extensive medium-sized drusen with pigment abnormalities.22 Quality control was provided by a resampling and regrading of 10% of the photographs by the reading center project ophthalmologist (RPD).

Retinal vascular indices were determined in a semiautomated manner as previously described.19,25 Briefly, the six largest arterioles and venules in a ring-shaped area located between 0.5 and 1.0 disc diameter from the optic margin were identified. Computer software measured the caliber of these individual vessels, then combined them into two summary variables for the eye: the projected caliber sizes of the central retinal artery equivalent (CRAE) and of the central retinal vein equivalent (CRVE). Because drusen are difficult to evaluate in the face of extensive retinal necrosis and scarring from cytomegalovirus (CMV) retinitis, eyes with ocular opportunistic infections were not graded, and these participants were not included in the AMD study.20

**Statistical Methods**

The association of the presence of AMD at baseline with characteristics of the study population was assessed using the χ² test for categorical variables, the t-test for normally distributed continuous variables, and the Wilcoxon rank sum test for non-normally distributed continuous variables.27 Multiple linear regression was used to assess relationships of CRAE and CRVE with presence of AMD in three models: unadjusted, adjusted for age, and adjusted for age and other baseline covariates. P values were two-sided and nominal. Statistical analyses were conducted with SAS/STAT, version 9.3 (SAS Institute, Inc., Cary, NC, USA) and Stata version 15.0 (StataCorp, College Station, TX, USA) software packages.

**Results**

**Characteristics of the Study Population**

Of the 2392 participants enrolled in LSOCA, 535 had an intraocular opportunistic infection (primarily CMV retinitis) and could not be assessed for AMD, leaving 1857 participants. Of these, 1583 were assessed for AMD from the enrollment photographs. Of these 1583 participants, 1171 also were assessed for AMD from enrollment photographs. The 1171 participants assessed for both AMD and retinal vascular caliber form the study population. Of these 1171 patients, 110 (9.4%) had intermediate-stage AMD, and 1061 (90.6%) did not.

Baseline (enrollment) characteristics of the study population and of participants with and without AMD are listed in Table 1. There were no significant differences between participants with and without AMD with respect to sex, race/ethnicity, time since AIDS diagnosis, enrollment CD4+ T cells before enrollment, HIV load at enrollment, maximum HIV load before enrollment, use of cART, and comorbidities. Participants with AMD were older (mean age 47.0 ± 8.3 years) than those without AMD (mean age 42.6 ± 8.0 years, P < 0.0001) and appeared to have a greater proportion of participants whose HIV transmission category was either injection drug use or heterosexual transmission (P = 0.04; see Table 1).

**Retinal Vascular Caliber**

Participants with AMD had larger CRAE and CRVE than participants without AMD (Table 1; Figs. 1, 2). The mean (± SD) CRAEs for participants with and without AMD were 151 ± 16 μm and 147 ± 16 μm, respectively (P < 0.0009). The mean (± SD CRVEs for participants with and without AMD were 228 ± 24 μm and 223 ± 25 μm, respectively (P = 0.02). The mean CRAE and CRVE declined with age for participants with and without AMD, but were consistently larger for participants with AMD (Figs. 1, 2, respectively). The adjusted differences in
CRAE and CRVE between those with and without AMD were even greater in the multiple linear regression analyses (Table 2). In the model adjusted for age, race/ethnicity, sex, HIV transmission category, smoking, enrollment and before enrollment nadir CD4⁺ T cells, enrollment and prior maximum HIV load, the difference in mean CRAE between those with and without AMD was 5.4 μm (95% confidence interval [CI] 2.3–8.5; \( P = 0.001 \)), and the difference in mean CRVE between

### Table 1. Univariate Analysis of Baseline Patient Characteristics and Prevalent Intermediate-stage AMD in Patients With AIDS Enrolled in LSOCA

|                        | No AMD | AMD  | Total | \( P \) |
|------------------------|--------|------|-------|--------|
| Number of patients     | 1061   | 110  | 1171  |        |
| **Demographics**       |        |      |       |        |
| Age, y, mean ± SD      | 42.6 ± 8.0 | 47.0 ± 8.3 | 43.0 ± 8.2 | <0.0001 |
| Sex, % men             | 81.1   | 76.4 | 80.6  | 0.25   |
| Race/ethnicity, %      |        |      |       | 0.69   |
| White, non-Hispanic    | 48.4   | 43.6 | 48.0  |        |
| African American       | 33.6   | 35.4 | 33.7  |        |
| Hispanic               | 15.0   | 16.4 | 15.1  |        |
| Other                  | 3.0    | 4.6  | 3.2   |        |
| Smoking history, %     |        |      |       | 0.58   |
| Current                | 41.2   | 37.8 | 40.9  |        |
| Former                 | 35.8   | 34.2 | 35.6  |        |
| Never                  | 23.0   | 28.0 | 23.4  |        |
| **AIDS history**       |        |      |       |        |
| Time since AIDS diagnosis, y, median [25th, 75th percentile] | 4.3 [1.7, 6.9] | 4.4 [1.1, 7.2] | 4.3 [1.6, 7.0] | 0.92 |
| HIV transmission category, % |        |      |       | 0.04   |
| Injection drug use (IDU) | 13.7 | 15.4 | 13.8  |        |
| Male-to-male sexual contact and no IDU | 55.6 | 43.6 | 54.5  |        |
| Heterosexual contact   | 25.5   | 37.3 | 26.6  |        |
| Other                  | 5.2    | 3.6  | 5.0   |        |
| **Immunology and virology** |        |      |       |        |
| Enrollment CD4⁺ T cells, cells/μL, median [25th, 75th percentile] | 189 [77, 345] | 189 [91, 295] | 189 [79, 342] | 0.88 |
| Nadir prior CD4⁺ T cells, cells/μL, median [25th, 75th percentile] | 40 [12, 107] | 49 [20, 120] | 41 [13, 110] | 0.14 |
| Enrollment HIV load, log_{10}(copies/mL), mean ± SD | 3.3 ± 1.4 | 3.4 ± 1.4 | 3.5 ± 1.4 | 0.73 |
| Maximum prior HIV load, log_{10}(copies/mL), mean ± SD | 5.0 ± 1.0 | 5.1 ± 0.9 | 5.0 ± 1.0 | 0.76 |
| **HIV treatment**      |        |      |       |        |
| cART* at enrollment, % | 82.4   | 85.4 | 82.7  | 0.51   |
| **Comorbidities at enrollment, %** |        |      |       |        |
| Diabetes               | 8.3    | 9.1  | 8.4   | 0.77   |
| Hyperlipidemia         | 21.1   | 20.0 | 21.0  | 0.80   |
| Elevated serum creatinine | 5.3  | 5.4  | 5.3   | 0.94   |
| Hypertension           | 18.7   | 22.7 | 19.0  | 0.30   |
| Cardiovascular disease | 13.3   | 18.5 | 13.7  | 0.19   |
| Hepatitis C infection, % seropositive | 21.6 | 22.3 | 21.7  | 0.86   |
| **Retinal vascular caliber, mean ± SD** |        |      |       |        |
| CRAE, μm               | 147 ± 16 | 151 ± 16 | 147 ± 16 | 0.009  |
| CRVE, μm               | 223 ± 25 | 228 ± 24 | 223 ± 25 | 0.02   |

* cART = combination therapy including at least one potent antiretroviral drug (e.g., a protease inhibitor).
Model 1: AMD

Model 2: AMD + age

Model 3: AMD + age + other baseline characteristics*  

* Other includes race/ethnicity, sex, HIV risk group, smoking status, enrollment CD4+ T cells, nadir CD4+ T cells, enrollment HIV load, maximum HIV load.

those with and without AMD was 6.0 μm (95% CI 1.4–10.6; P = 0.01).

DISCUSSION

We previously reported that patients with AIDS had an approximately 4-fold increased prevalence of intermediate-stage AMD and an approximately 1.75-fold increased incidence of intermediate-stage AMD, consistent with the accelerated/acculturated aging phenotype present in antiretroviral-treated, immune-restored, HIV-infected persons. In this study, we demonstrate that persons with AIDS have larger retinal arteriolar and venular calibers than HIV-infected persons without AMD. Previous work in HIV-uninfected populations has demonstrated several risk factors for changes in retinal vascular caliber. Older age is associated with narrower retinal vascular caliber, and hypertension is associated with narrower retinal arterioles; conversely, cigarette smoking is associated with wider retinal arterioles and venules; although some studies have reported a greater effect on venules. Biomarkers of systemic inflammation consistently are associated with wider retinal venules. In our study, both retinal arteriolar caliber and venular caliber were greater among persons with AMD. This effect was consistent across age, and adjustments for baseline parameters only increased the estimated difference. Our study did show an age-related decline in both CRAE and CRVE in both persons with and without AMD, as is seen in HIV-uninfected persons, but the CRAE and CRVE consistently were larger among patients with AMD than those without.

Antiretroviral-treated, immune-restored, HIV-infected persons have immunologic changes similar to those seen in HIV-uninfected persons older than 70 years, a phenomenon sometimes termed immunosenescence. Antiretroviral-treated, immune-restored, HIV-infected persons are characterized by a state of chronic immune activation with ongoing systemic inflammation. Studies in HIV-uninfected persons demonstrate that systemic inflammation is a risk factor for AMD. Therefore, the increased retinal venular caliber in HIV-infected persons with AMD may relate to the common role of systemic inflammation in the pathogenesis of AMD and in altered retinal vascular caliber. Nevertheless, it also is possible that other, unobservable factors are responsible for both the occurrence of AMD and vascular dilation in these patients.

Caution should be taken in interpreting our data. Although the AMD lesions seen in the LSOCA population are clinically and photographically identical to those seen in HIV-uninfected populations, we do not have histology to confirm the nature of the lesions. Caution also should be taken in extrapolating our data to all HIV-infected persons. The LSOCA cohort enrolled only persons with AIDS and not earlier stages of HIV infection. The nadir CD4+ T cells were very low, even though many participants had substantial immune recovery by enrollment. The effects of such levels of immune deficiency on subsequent immune activation and systemic inflammation may be different from those seen in HIV-infected patients who never reach this level of immune deficiency. As such, the prevalence and incidence of AMD in HIV-infected patients with earlier stages of HIV infection remain uncertain. Nevertheless, because of late diagnosis and difficulties in completely suppressing HIV replication among all patients, many individuals with HIV infection will present with or progress to AIDS, so that there remains a population of HIV-infected patients who will progress to AIDS and for whom these results are relevant. Furthermore, the LSOCA cohort is similar to the AIDS epidemic in the United States in terms of demographic and other characteristics, suggesting some degree of generalizability to patients with AIDS. Finally, we only could analyze (and adjust for) those factors where we had data from the LSOCA cohort study. As such, it is possible that other, unobservable factors may contribute to both AMD and retinal vascular dilation in this population.

In sum, LSOCA data demonstrate increased retinal vascular caliber, both CRAE and CRVE, in persons with AIDS and AMD. The relationship of systemic inflammation to AMD in HIV-uninfected persons and to increased retinal venular caliber, as well as the state of chronic immune activation and systemic inflammation among antiretroviral-treated HIV-infected persons, suggest a possible common pathogenic role for inflammation in both of these findings.

Acknowledgments

Supported by Grant R01 EY025093 from the National Eye Institute, the National Institutes of Health, Bethesda, MD, USA to the Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Disclosure: D.A. Jabs, None; M.L. Van Natta, None; J.W. Pak, None; R.P. Danis, None; P.W. Hunt, None.

References

1. Frieden DS, O’Colmain B, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–572.
2. Congdon N, O’Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–485.
3. Wang WL, Su X, Cheung CMG, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review. Lancet. 2014;3:106–116.
4. Davis MD, Gangon RE, Lee LY, et al. The Age-Related Eye Disease Study severity scale for age-related macular degener-
12. Deeks SG. HIV infection, inflammation, immunosenescence. 2010;12:1570–1574.
13. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with advanced human immunodeficiency virus infection. 1998;338:853–860.
14. Hogg R, Lima V, Sterne JA, et al. Life expectancy of individuals with and without HIV infection in Denmark, 1995–2005. 2007;146:87–95.
15. Kaplan RC, Kingsley LA, Sarrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. 2007;45:1074–1081.
16. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? 2012;153:1016–1024.
17. Jabs DA, Van Natta ML, Pak JW, Danis RP. Incidence of intermediate-stage age-related macular degeneration in patients with acquired immunodeficiency syndrome. 2015;159:1115–1122.
18. Gangaputra S, Kaylani PS, Fawzi AA, et al; for the Studies of the Ocular Complications of AIDS Research Group. Prevalence of intermediate-stage age-related macular degeneration among adolescents and adults. 1992;41:11–19.
19. Siddiqui S, Kaylani PS, Fawzi AA, et al; for the Studies of the Ocular Complications of AIDS: 1. Ocular diagnoses at enrollment. 2012;153:434–444.
20. Jabs DA, Van Natta ML, Holbrook JT, et al. The Longitudinal Study of the Ocular Complications of AIDS: 1. Ocular examination results at enrollment. 2007;114:787–793.
21. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. 1992;41:1–19.